Established resistance mechanisms

The main mutations and bypass pathways that may accumulate while ER-positive cells survive in autophagy or senescence

McGrath et al. (2024) do not claim that autophagy and senescence are the whole resistance story.

They treat them as the bridge into the better-known resistance mechanisms.

In other words, these survival states may buy time for more durable escape biology to appear.

Review we are unpacking

McGrath MK, Abolhassani A, Guy L, Elshazly AM, Barrett JT, Mivechi NF, Gewirtz DA, and Schoenlein PV (2024).

Autophagy and senescence facilitate the development of antiestrogen resistance in ER-positive breast cancer.

Frontiers in Endocrinology. 15:1298423.

URL: https://doi.org/10.3389/fendo.2024.1298423

ESR1 mutations

ESR1 mutations are among the most important resistance markers in ER-positive disease.

They matter because they can activate the estrogen receptor even when estrogen is low.

That helps cells bypass aromatase inhibition.

The authors highlight a few practical points:

many ESR1 mutations sit in the ligand-binding domain
they can emerge during treatment, not just exist from the start
they can be tracked in circulating tumour DNA
they now influence treatment switching in practice

This is one reason liquid biopsy matters more in endocrine-resistant disease.

CYP19A1 amplification

CYP19A1 encodes aromatase.

If the gene is amplified, cells can increase local estrogen production.

That can weaken aromatase-inhibitor control.

McGrath et al. (2024) note that CYP19A1 amplification often travels with ESR1 changes.

It also flags an interesting distinction.

This pattern appears more associated with the reversible non-steroidal aromatase inhibitors than with exemestane.

Bypass signalling through growth-factor pathways

Cancer cells do not always need the estrogen receptor to keep signalling.

They can route around it.

The authors emphasise:

PI3K / AKT / mTOR
HER2
MEK / MAPK
receptor tyrosine kinases such as EGFR, IGF-1R, and FGFR

These pathways can reactivate growth even while endocrine therapy stays in place.

This is where combinations such as everolimus plus exemestane make sense biologically.

It is also where targeted therapy can still fail if protective autophagy remains intact.

HSF1 as an emerging mechanism

McGrath et al. (2024) also highlight HSF1.

This is a stress-response regulator.

In resistant cell lines, high HSF1 was linked to lower ERα signalling and more antiestrogen independence.

That makes HSF1 interesting for two reasons.

It may support resistance directly.

It may also connect stress-response biology back to autophagy.

This is still an emerging area.

Why these mechanisms matter in this section

Pages on ESR1, PI3K, or HER2 bypass can look very mutation-focused.

McGrath et al. (2024) add another layer.

They suggest that the mutation-driven phase may develop while cells are being protected by autophagy or senescence.

That does not reduce the importance of ESR1 or PI3K.

It changes the timing question.

When did the cell get the chance to build that escape?

Where liquid biopsy fits

Liquid biopsy is useful here.

It can track some resistance changes before clinical collapse becomes obvious.

That is especially relevant for ESR1.

For a deeper page on that, see Blood Biopsy Trial — Getting Ahead of Treatment Resistance.

What liquid biopsy can and cannot tell you

Liquid biopsy can help track evolving mutations such as ESR1.

It cannot directly measure autophagy or senescence.

That means it is useful for the later resistance phase, but much weaker for the survival-state phase described in this review.

Bottom line

ESR1 mutations, aromatase-gene amplification, and bypass signalling remain core resistance mechanisms in ER-positive disease.

The authors place them in sequence.

First, cells survive.

Then, some of them evolve.

Autophagy and senescence may be the survival layer that lets the later resistance layer emerge.

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.